Glycopyrrolate Injection, USP recalled for manufacturing practice deviations
Accord Healthcare recalls Glycopyrrolate Injection USP following FDA inspection identifying manufacturing deviations. Approximately 23,814 vials distributed to the US, Puerto Rico, and Canada are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for manufacturing practice deviations in a prescription injectable drug product. Manufacturing deviations represent risk-of-harm despite no reported illnesses, meeting the rubric criterion for high-severity recalls.
Plain-English summary
Accord Healthcare, Inc. is recalling Glycopyrrolate Injection, USP 0.2 mg/mL due to manufacturing practice deviations identified during FDA inspection. The affected product consists of single-dose vials distributed to the United States, including Puerto Rico, and Canada.
The recall affects six batches: R2200436, R2200159, R2200166, R2200618, R2201290, and R2201324, with expiration dates ranging from January 2024 to August 2024. Approximately 23,814 vials were distributed.
Healthcare providers with affected inventory should contact Accord Healthcare, Inc. for instruction on how to proceed. This is a Class II recall initiated by the recalling firm.
The recalled product
- Product
- GLYCOPYRROLATE (GLYCOPYRROLATE)
- Brand
- GLYCOPYRROLATE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Prescription Injectable
- Hazard
- Affected units
- 23,814
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Batches: R2200436
- Exp. Date 1/31/2024
- R2200159
- R2200166
- R2200618
- Exp. Date 4/30/2024
- R2201290
- Exp. Date 8/31/2024
- R2201324
UPCs (6)
- 0316729474054
- 0316729472302
- 0316729473316
- 0316729471633
- 316729471633
- 316729471084
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · GLYCOPYRROLATE
- ModerateGlycopyrrolate Injection Recall Due to Hair Contamination
FDA (Drugs) · 2026-07-29
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateGlycopyrrolate oral solution recalled after failing impurity and degradation specifications
FDA (Drugs) · 2026-02-04
- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- ModerateGlycopyrrolate Injection Vials Recalled Due to Labeling Mix-up
FDA (Drugs) · 2023-06-14
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29